Topical effectiveness of molgramostim (GM-CSF) in sickle cell leg ulcers

Dermatology. 2004;208(2):135-7. doi: 10.1159/000076487.

Abstract

Background: Leg ulcers are a frequently neglected, severe complication of sickle cell disease (SCD), responsible for significant altering quality of life. The management of leg ulcers remains disappointing. Local application of recombinant human granulocyte-macrophage colony-stimulating factor has been shown to be effective in several types of chronic wound healing.

Methods: We report 5 homozygous sickle cell patients with 14 leg ulcers lasting from 1 month to 6 years, treated with topical dripping of molgramostim solution.

Results: Healing was obtained for 9/14 ulcers, with no local or systemic adverse reactions.

Comments: Molgramostim solution appears to be an adequate therapy for SCD leg ulcers but a more conclusive evaluation will depend on larger series of patients and other types of formulations for topical applications could be even more effective in the future.

MeSH terms

  • Administration, Topical
  • Adult
  • Anemia, Sickle Cell / complications*
  • Anemia, Sickle Cell / diagnosis
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage*
  • Humans
  • Leg Ulcer / complications*
  • Leg Ulcer / diagnosis
  • Leg Ulcer / drug therapy*
  • Male
  • Prognosis
  • Recombinant Proteins / administration & dosage*
  • Sampling Studies
  • Severity of Illness Index
  • Treatment Outcome
  • Wound Healing / drug effects
  • Wound Healing / physiology

Substances

  • Recombinant Proteins
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • molgramostim